Alvotech ALVO

NAS: ALVO | ISIN: LU2458332611   12/09/2025
8,030 USD (-0,25%)
(-0,25%)   12/09/2025

4 september 2025 · Alvotech Meets Investors and Participates in a Fireside Chat at the Morgan Stanley 23rd Annual Global Healthcare Conference in New York · Persbericht

21 augustus 2025 · Advanz Pharma and Alvotech receive European approval for Mynzepli®, Biosimilar to Eylea® · Persbericht

20 augustus 2025 · Alvotech appoints Patrik Ling as VP of Investor Relations Scandinavia · Persbericht

13 augustus 2025 · Alvotech Reports Results for the First Six Months of 2025 and Provides a Business Update · Persbericht

6 augustus 2025 · Alvotech Announces Webcast to Report Financial Results for the First Half of 2025 on August 14, 2025, at 8:00 am EDT · Persbericht

10 juli 2025 · Alvotech Appoints Linda Jónsdóttir as Chief Financial Officer · Persbericht

9 juli 2025 · Alvotech Expands its Capacity in Assembly and Packaging with the Acquisition of Ivers-Lee Group in Switzerland · Persbericht

4 juli 2025 · Notification for the purposes of article 13 of the Luxembourg law of 11 January 2008 on transparency requirements for issuers     · Persbericht

2 juli 2025 · Granting of Stock Options and Vesting of Restricted Share Units · Persbericht

1 juli 2025 · Alvotech and Advanz Pharma Enter into European Supply and Commercialization Agreement for Biosimilar Candidate to Cimzia® (certolizumab pegol) · Persbericht

26 juni 2025 · Alvotech’s Lenders Lower Interest on Senior Secured Term Loan Facility · Persbericht

25 juni 2025 · Main Results of 2025 Annual and Extraordinary General Meeting · Persbericht

25 juni 2025 · Positive Top Line Results from Confirmatory Efficacy Study for Proposed Biosimilar to Xolair® (omalizumab) · Persbericht

23 juni 2025 · European Medicines Agency Recommends Market Approval of AVT06, Alvotech’s Proposed Biosimilar to Eylea® (aflibercept) · Persbericht

11 juni 2025 · Alvotech’s Private Placement Completed with Delivery of SDRs and Shares to Investors · Persbericht

6 juni 2025 · Alvotech Participates in the Goldman Sachs Global Healthcare Conference in Miami · Persbericht

5 juni 2025 · Alvotech and Dr. Reddy’s Enter into Collaboration to Co-Develop Biosimilar Candidate to Keytruda® (pembrolizumab) · Persbericht

5 juni 2025 · Alvotech has carried out a private placement of 7,500,000 SDRs and ordinary shares at a price of SEK 100.00 per SDR and ISK 1320.83 per ordinary share, raising gross proceeds of SEK 750 million · Persbericht

4 juni 2025 · Alvotech intends to carry out a private placement of approximately 7.5 million SDRs and ordinary shares · Persbericht

4 juni 2025 · Alvotech Completes Acquisition of Xbrane R&D Organization and biosimilar candidate to Cimzia® · Persbericht

Mijn selecties